Antares, Novartis pursuing undruggable cancer targets in $1.9B deal

▤ Summary

Novartis and Antares have entered a collaboration that could total $1.9 billion, centered on discovering small-molecule programs for oncology targets viewed as undruggable. The deal includes a $105 million upfront payment and gives Antares its first partnership since spinning out of Scorpion Therapeutics. This is a major life sciences transaction and signals continued investment in difficult cancer-target discovery. The news is relevant to software and ISV readers mainly because it sits in the pharma/life sciences sector, but it is not a software product or company-operations story.

▦ Linked Companies